ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Berberine reshapes gut microbiota and attenuates bone loss in estrogen-deficient osteoporosis via the gut-bone axis.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Postmenopausal osteoporosis (PMO) is a metabolic bone disorder characterized by estrogen deficiency-induced bone loss, deterioration of bone microstructure, and increased fracture risk. Current therapeutic agents are limited in efficacy and may have adverse effects. Berberine, a traditional Chinese medicinal compound, exhibits multitarget regulatory potential. However, its mechanism of action in alleviating PMO through modulation of the gut microbiota remains unclear. The objectives of this study are to assess the potential of berberine in mitigating estrogen deficiency-induced osteoporosis through modulation of the gut microbiota and to elucidate its underlying mechanisms. An ovariectomy (OVX)-induced PMO mouse model was established and divided into control, model, and berberine-treated (100 mg/kg/day) groups. Bone microstructure was examined using micro-CT, gut microbiota composition was analyzed through 16S rRNA sequencing; inflammatory factors and bone metabolism markers were evaluated using immunofluorescence; western blotting, qRT-PCR, and serum cytokine levels were quantified using ELISA. Berberine effectively reversed the OVX-induced gut dysbiosis by restoring the diminished levels of norank_f_Muribaculaceae and mitigating the elevated abundance of Lachnospiraceae_NK4A136_group, norank_f_Lachnospiraceae, and Roseburia. This modulation led to the suppression of intestinal inflammation, evidenced by decreased expression of IL-1β, IL-6, IL-8, and TNF-α, and an enhancement in gut barrier integrity, as indicated by increased levels of occludin and ZO-1. These changes collectively reduced the translocation of LPS into circulation. Consequently, berberine attenuated systemic and local release of pro-inflammatory cytokines and the activation of osteoclasts, resulting in the amelioration of PMO. Berberine mitigates PMO by reshaping the gut microbiota, improving intestinal barrier function, and suppressing systemic inflammation, thereby inhibiting bone resorption and restoring bone metabolic balance. This study offers a novel microbiome-targeted therapeutic approach for PMO.
Indexed as
Identifiers
42168404What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.